Which has preferable earnings and valuation, LFCR or RADX?

Radiopharm Theranostics has lower revenue, but higher earnings than Lifecore Biomedical. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Lifecore Biomedical $128.87M 1.55 -$35.26M -$0.94 N/A Radiopharm Theranostics $2.35M 21.86 -$24.83M N/A N/A

Does the media refer more to LFCR or RADX?

In the previous week, Lifecore Biomedical and Lifecore Biomedical both had 2 articles in the media. Lifecore Biomedical's average media sentiment score of 1.32 beat Radiopharm Theranostics' score of 0.94 indicating that Lifecore Biomedical is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Lifecore Biomedical 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Radiopharm Theranostics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has better earnings and valuation, ALXO or RADX?

Radiopharm Theranostics has higher revenue and earnings than ALX Oncology. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio ALX Oncology N/A N/A -$101.69M -$1.49 N/A Radiopharm Theranostics $2.35M 21.86 -$24.83M N/A N/A

Is ALXO or RADX more profitable?

Radiopharm Theranostics' return on equity of 0.00% beat ALX Oncology's return on equity. Company Net Margins Return on Equity Return on Assets ALX Oncology N/A -124.06% -85.57% Radiopharm Theranostics N/A N/A N/A

Does the media refer more to ALXO or RADX?

In the previous week, ALX Oncology had 2 more articles in the media than Radiopharm Theranostics. MarketBeat recorded 4 mentions for ALX Oncology and 2 mentions for Radiopharm Theranostics. Radiopharm Theranostics' average media sentiment score of 0.94 beat ALX Oncology's score of 0.47 indicating that Radiopharm Theranostics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment ALX Oncology 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Radiopharm Theranostics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has stronger earnings and valuation, RADX or HUMA?

Radiopharm Theranostics has higher revenue and earnings than Humacyte. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Radiopharm Theranostics $2.35M 21.86 -$24.83M N/A N/A Humacyte $2.04M 77.49 -$40.83M -$0.57 N/A

Does the media prefer RADX or HUMA?

In the previous week, Humacyte had 1 more articles in the media than Radiopharm Theranostics. MarketBeat recorded 3 mentions for Humacyte and 2 mentions for Radiopharm Theranostics. Radiopharm Theranostics' average media sentiment score of 0.94 beat Humacyte's score of 0.43 indicating that Radiopharm Theranostics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Radiopharm Theranostics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Humacyte 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has higher earnings and valuation, RADX or NKTX?

Radiopharm Theranostics has higher revenue and earnings than Nkarta. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Radiopharm Theranostics $2.35M 21.86 -$24.83M N/A N/A Nkarta N/A N/A -$104.08M -$1.34 N/A

Is RADX or NKTX more profitable?

Radiopharm Theranostics' return on equity of 0.00% beat Nkarta's return on equity. Company Net Margins Return on Equity Return on Assets Radiopharm Theranostics N/A N/A N/A Nkarta N/A -30.90% -24.20%

Does the media prefer RADX or NKTX?

In the previous week, Radiopharm Theranostics and Radiopharm Theranostics both had 2 articles in the media. Radiopharm Theranostics' average media sentiment score of 0.94 equaled Nkarta'saverage media sentiment score. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Radiopharm Theranostics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Nkarta 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has preferable earnings and valuation, RADX or QTTB?

Q32 Bio has higher revenue and earnings than Radiopharm Theranostics. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Radiopharm Theranostics $2.35M 21.86 -$24.83M N/A N/A Q32 Bio $53.74M 3.99 $29.82M $2.66 4.75

Is RADX or QTTB more profitable?

Q32 Bio's return on equity of 149.23% beat Radiopharm Theranostics' return on equity. Company Net Margins Return on Equity Return on Assets Radiopharm Theranostics N/A N/A N/A Q32 Bio N/A 149.23% 34.50%

Radiopharm Theranostics (RADX) Competitors

$4.35 +0.16 (+3.82%)

As of 02:37 PM Eastern

Compare

RADX vs. LFCR, ALXO, HUMA, NKTX, and QTTB

Should you buy Radiopharm Theranostics stock or one of its competitors? MarketBeat compares Radiopharm Theranostics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Radiopharm Theranostics include Lifecore Biomedical (LFCR), ALX Oncology (ALXO), Humacyte (HUMA), Nkarta (NKTX), and Q32 Bio (QTTB). These companies are all part of the "med - biomed/gene" industry.

How does Radiopharm Theranostics compare to Lifecore Biomedical?

Lifecore Biomedical (NASDAQ:LFCR) and Radiopharm Theranostics (NASDAQ:RADX) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their profitability, risk, dividends, earnings, institutional ownership, analyst recommendations, valuation and media sentiment.

In the previous week, Lifecore Biomedical and Lifecore Biomedical both had 2 articles in the media. Lifecore Biomedical's average media sentiment score of 1.32 beat Radiopharm Theranostics' score of 0.94 indicating that Lifecore Biomedical is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Lifecore Biomedical	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Radiopharm Theranostics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

83.4% of Lifecore Biomedical shares are held by institutional investors. 32.7% of Lifecore Biomedical shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Radiopharm Theranostics has lower revenue, but higher earnings than Lifecore Biomedical.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Lifecore Biomedical	$128.87M	1.55	-$35.26M	-$0.94	N/A
Radiopharm Theranostics	$2.35M	21.86	-$24.83M	N/A	N/A

Lifecore Biomedical presently has a consensus target price of $6.50, indicating a potential upside of 22.16%. Radiopharm Theranostics has a consensus target price of $11.00, indicating a potential upside of 152.87%. Given Radiopharm Theranostics' stronger consensus rating and higher probable upside, analysts clearly believe Radiopharm Theranostics is more favorable than Lifecore Biomedical.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Lifecore Biomedical	1 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Radiopharm Theranostics	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33

Radiopharm Theranostics has a net margin of 0.00% compared to Lifecore Biomedical's net margin of -25.43%. Radiopharm Theranostics' return on equity of 0.00% beat Lifecore Biomedical's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Lifecore Biomedical	-25.43%	-1,643.15%	-14.40%
Radiopharm Theranostics	N/A	N/A	N/A

Lifecore Biomedical has a beta of 1.06, meaning that its share price is 6% more volatile than the broader market. Comparatively, Radiopharm Theranostics has a beta of 1.34, meaning that its share price is 34% more volatile than the broader market.

Summary

Radiopharm Theranostics beats Lifecore Biomedical on 9 of the 13 factors compared between the two stocks.

How does Radiopharm Theranostics compare to ALX Oncology?

ALX Oncology (NASDAQ:ALXO) and Radiopharm Theranostics (NASDAQ:RADX) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their valuation, risk, profitability, institutional ownership, media sentiment, dividends, earnings and analyst recommendations.

Radiopharm Theranostics' return on equity of 0.00% beat ALX Oncology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
ALX Oncology	N/A	-124.06%	-85.57%
Radiopharm Theranostics	N/A	N/A	N/A

ALX Oncology presently has a consensus price target of $4.60, suggesting a potential upside of 120.62%. Radiopharm Theranostics has a consensus price target of $11.00, suggesting a potential upside of 152.87%. Given Radiopharm Theranostics' higher possible upside, analysts plainly believe Radiopharm Theranostics is more favorable than ALX Oncology.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ALX Oncology	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.67
Radiopharm Theranostics	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33

In the previous week, ALX Oncology had 2 more articles in the media than Radiopharm Theranostics. MarketBeat recorded 4 mentions for ALX Oncology and 2 mentions for Radiopharm Theranostics. Radiopharm Theranostics' average media sentiment score of 0.94 beat ALX Oncology's score of 0.47 indicating that Radiopharm Theranostics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
ALX Oncology	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Radiopharm Theranostics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

ALX Oncology has a beta of 0.44, meaning that its share price is 56% less volatile than the broader market. Comparatively, Radiopharm Theranostics has a beta of 1.34, meaning that its share price is 34% more volatile than the broader market.

98.0% of ALX Oncology shares are owned by institutional investors. 21.0% of ALX Oncology shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Radiopharm Theranostics has higher revenue and earnings than ALX Oncology.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ALX Oncology	N/A	N/A	-$101.69M	-$1.49	N/A
Radiopharm Theranostics	$2.35M	21.86	-$24.83M	N/A	N/A

Summary

Radiopharm Theranostics beats ALX Oncology on 7 of the 12 factors compared between the two stocks.

How does Radiopharm Theranostics compare to Humacyte?

Radiopharm Theranostics (NASDAQ:RADX) and Humacyte (NASDAQ:HUMA) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their dividends, valuation, analyst recommendations, profitability, risk, media sentiment, earnings and institutional ownership.

44.7% of Humacyte shares are owned by institutional investors. 3.1% of Humacyte shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Radiopharm Theranostics has higher revenue and earnings than Humacyte.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Radiopharm Theranostics	$2.35M	21.86	-$24.83M	N/A	N/A
Humacyte	$2.04M	77.49	-$40.83M	-$0.57	N/A

Radiopharm Theranostics has a beta of 1.34, indicating that its stock price is 34% more volatile than the broader market. Comparatively, Humacyte has a beta of 2.45, indicating that its stock price is 145% more volatile than the broader market.

Radiopharm Theranostics has a net margin of 0.00% compared to Humacyte's net margin of -4,836.06%. Radiopharm Theranostics' return on equity of 0.00% beat Humacyte's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Radiopharm Theranostics	N/A	N/A	N/A
Humacyte	-4,836.06%	-2,914.18%	-89.45%

In the previous week, Humacyte had 1 more articles in the media than Radiopharm Theranostics. MarketBeat recorded 3 mentions for Humacyte and 2 mentions for Radiopharm Theranostics. Radiopharm Theranostics' average media sentiment score of 0.94 beat Humacyte's score of 0.43 indicating that Radiopharm Theranostics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Radiopharm Theranostics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Humacyte	2 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Radiopharm Theranostics currently has a consensus price target of $11.00, indicating a potential upside of 152.87%. Humacyte has a consensus price target of $6.25, indicating a potential upside of 777.81%. Given Humacyte's stronger consensus rating and higher probable upside, analysts clearly believe Humacyte is more favorable than Radiopharm Theranostics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Radiopharm Theranostics	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33
Humacyte	1 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.75

Summary

Humacyte beats Radiopharm Theranostics on 8 of the 14 factors compared between the two stocks.

How does Radiopharm Theranostics compare to Nkarta?

Radiopharm Theranostics (NASDAQ:RADX) and Nkarta (NASDAQ:NKTX) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their analyst recommendations, dividends, risk, media sentiment, valuation, earnings, profitability and institutional ownership.

80.5% of Nkarta shares are held by institutional investors. 9.8% of Nkarta shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Radiopharm Theranostics' return on equity of 0.00% beat Nkarta's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Radiopharm Theranostics	N/A	N/A	N/A
Nkarta	N/A	-30.90%	-24.20%

In the previous week, Radiopharm Theranostics and Radiopharm Theranostics both had 2 articles in the media. Radiopharm Theranostics' average media sentiment score of 0.94 equaled Nkarta'saverage media sentiment score.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Radiopharm Theranostics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Nkarta	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Radiopharm Theranostics has a beta of 1.34, indicating that its share price is 34% more volatile than the broader market. Comparatively, Nkarta has a beta of 0.91, indicating that its share price is 9% less volatile than the broader market.

Radiopharm Theranostics presently has a consensus price target of $11.00, indicating a potential upside of 152.87%. Nkarta has a consensus price target of $10.75, indicating a potential upside of 276.53%. Given Nkarta's stronger consensus rating and higher probable upside, analysts plainly believe Nkarta is more favorable than Radiopharm Theranostics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Radiopharm Theranostics	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33
Nkarta	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.83

Radiopharm Theranostics has higher revenue and earnings than Nkarta.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Radiopharm Theranostics	$2.35M	21.86	-$24.83M	N/A	N/A
Nkarta	N/A	N/A	-$104.08M	-$1.34	N/A

Summary

Nkarta beats Radiopharm Theranostics on 6 of the 11 factors compared between the two stocks.

How does Radiopharm Theranostics compare to Q32 Bio?

Radiopharm Theranostics (NASDAQ:RADX) and Q32 Bio (NASDAQ:QTTB) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, profitability, media sentiment, earnings, risk, dividends, valuation and analyst recommendations.

Radiopharm Theranostics has a beta of 1.34, suggesting that its share price is 34% more volatile than the broader market. Comparatively, Q32 Bio has a beta of 0.27, suggesting that its share price is 73% less volatile than the broader market.

Q32 Bio has higher revenue and earnings than Radiopharm Theranostics.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Radiopharm Theranostics	$2.35M	21.86	-$24.83M	N/A	N/A
Q32 Bio	$53.74M	3.99	$29.82M	$2.66	4.75

In the previous week, Radiopharm Theranostics had 1 more articles in the media than Q32 Bio. MarketBeat recorded 2 mentions for Radiopharm Theranostics and 1 mentions for Q32 Bio. Q32 Bio's average media sentiment score of 1.89 beat Radiopharm Theranostics' score of 0.94 indicating that Q32 Bio is being referred to more favorably in the news media.

Company	Overall Sentiment
Radiopharm Theranostics	Positive
Q32 Bio	Very Positive

Q32 Bio's return on equity of 149.23% beat Radiopharm Theranostics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Radiopharm Theranostics	N/A	N/A	N/A
Q32 Bio	N/A	149.23%	34.50%

31.3% of Q32 Bio shares are owned by institutional investors. 34.5% of Q32 Bio shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Radiopharm Theranostics currently has a consensus price target of $11.00, indicating a potential upside of 152.87%. Q32 Bio has a consensus price target of $13.50, indicating a potential upside of 6.80%. Given Radiopharm Theranostics' higher possible upside, equities research analysts plainly believe Radiopharm Theranostics is more favorable than Q32 Bio.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Radiopharm Theranostics	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33
Q32 Bio	0 Sell rating(s)	2 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.60

Summary

Q32 Bio beats Radiopharm Theranostics on 9 of the 13 factors compared between the two stocks.

Get Radiopharm Theranostics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding RADX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

RADX vs. The Competition

Export

Metric	Radiopharm Theranostics	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$51.37M	$3.64B	$6.78B	$12.59B
Dividend Yield	N/A	2.20%	2.66%	6.15%
P/E Ratio	N/A	21.43	27.44	25.41
Price / Sales	21.86	341.02	582.70	119.35
Price / Cash	N/A	143.77	48.53	58.59
Price / Book	1.24	8.66	10.93	6.64
Net Income	-$24.83M	$23.87M	$3.57B	$336.83M
7 Day Performance	5.07%	3.48%	2.68%	2.93%
1 Month Performance	-7.05%	3.48%	1.77%	0.54%
1 Year Performance	1.40%	66.58%	35.99%	30.13%

Radiopharm Theranostics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
RADX Radiopharm Theranostics	4.0033 of 5 stars	$4.35 +3.8%	$11.00 +152.9%	-9.7%	$51.37M	$2.35M	N/A	N/A	Gap Up
LFCR Lifecore Biomedical	1.588 of 5 stars	$5.54 flat	$6.50 +17.3%	-35.3%	$207.80M	$128.87M	N/A	690	News Coverage
ALXO ALX Oncology	3.2925 of 5 stars	$1.53 flat	$4.60 +200.7%	+398.7%	$205.88M	N/A	N/A	40	News Coverage High Trading Volume
HUMA Humacyte	4.02 of 5 stars	$0.92 flat	$6.25 +576.1%	-62.7%	$205.23M	$2.04M	N/A	150
NKTX Nkarta	4.1943 of 5 stars	$2.86 flat	$10.75 +275.9%	+70.5%	$204.62M	N/A	N/A	140

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:RADX) was last updated on 7/1/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Radiopharm Theranostics (RADX) Competitors

RADX vs. LFCR, ALXO, HUMA, NKTX, and QTTB

How does Radiopharm Theranostics compare to Lifecore Biomedical?

Summary

How does Radiopharm Theranostics compare to ALX Oncology?

Summary

How does Radiopharm Theranostics compare to Humacyte?

Summary

How does Radiopharm Theranostics compare to Nkarta?

Summary

How does Radiopharm Theranostics compare to Q32 Bio?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

RADX vs. The Competition

Radiopharm Theranostics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Radiopharm Theranostics (RADX) Competitors

RADX vs. LFCR, ALXO, HUMA, NKTX, and QTTB

How does Radiopharm Theranostics compare to Lifecore Biomedical?

Does the media refer more to LFCR or RADX?

Do institutionals & insiders believe in LFCR or RADX?

Which has preferable earnings and valuation, LFCR or RADX?

Do analysts rate LFCR or RADX?

Is LFCR or RADX more profitable?

Which has more volatility & risk, LFCR or RADX?

Summary

How does Radiopharm Theranostics compare to ALX Oncology?

Is ALXO or RADX more profitable?

Do analysts prefer ALXO or RADX?

Does the media refer more to ALXO or RADX?

Which has more risk & volatility, ALXO or RADX?

Do insiders & institutionals hold more shares of ALXO or RADX?

Which has better earnings and valuation, ALXO or RADX?

Summary

How does Radiopharm Theranostics compare to Humacyte?

Do insiders & institutionals have more ownership in RADX or HUMA?

Which has stronger earnings and valuation, RADX or HUMA?

Which has more risk & volatility, RADX or HUMA?

Is RADX or HUMA more profitable?

Does the media prefer RADX or HUMA?

Do analysts rate RADX or HUMA?

Summary

How does Radiopharm Theranostics compare to Nkarta?

Do insiders & institutionals have more ownership in RADX or NKTX?

Is RADX or NKTX more profitable?

Does the media prefer RADX or NKTX?

Which has more risk and volatility, RADX or NKTX?

Do analysts recommend RADX or NKTX?

Which has higher earnings and valuation, RADX or NKTX?

Summary

How does Radiopharm Theranostics compare to Q32 Bio?

Which has more volatility and risk, RADX or QTTB?

Which has preferable earnings and valuation, RADX or QTTB?

Does the media prefer RADX or QTTB?

Is RADX or QTTB more profitable?

Do institutionals & insiders believe in RADX or QTTB?

Do analysts rate RADX or QTTB?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

RADX vs. The Competition

Radiopharm Theranostics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools